ReviewAPL bioengineering2021
Biofabrication of tissue engineering vascular systems.
Review in APL bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- In Vitro Evaluation of Escherichia coli and Staphylococcus aureus Translocation in 3D Printed Material.Journal of biomedical materials research. Part A · 2026Article
- Article
- Strategies for improved endothelial cell adhesion in microphysiological vascular model systems.PloS one · 2025Article
- Applications, challenges, and prospects of induced pluripotent stem cells for vascular disease.Molecules and cells · 2024Review
- Composite Tissue-Engineered Small-Diameter Vascular Grafts Based on Polycaprolactone and Polyurethane with Growth Factors and Atrombogenic Drug Coatings: Surface Ultrastructure, Physical and Mechanical Properties.Sovremennye tekhnologii v meditsine · 2024Article
- Biological Materials for Tissue-Engineered Vascular Grafts: Overview of Recent Advancements.Biomolecules · 2023Review
- Realizations of vascularized tissues: FromBiophysics reviews · 2023Review
- 3D bioprinting strategy for engineering vascularized tissue models.International journal of bioprinting · 2023Article
- From In Vitro to Perioperative Vascular Tissue Engineering: Shortening Production Time by Traceable Textile-Reinforcement.Tissue engineering and regenerative medicine · 2022Article
- Biofabrication of Collagen Tissue-Engineered Blood Vessels with Direct Co-Axial Extrusion.International journal of molecular sciences · 2022Article
- Structural Aspects of Electrospun Scaffolds Intended for Prosthetics of Blood Vessels.Polymers · 2022Review
- The Biofabrication of Diseased Artery In Vitro Models.Micromachines · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Cardiovascular disease (CVD) is the leading cause of death among persons aged 65 and older in the United States and many other developed countries. Tissue engineered vascular systems (TEVS) can serve as grafts for CVD treatment and be used as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.